Integrin Receptor Antagonist [EPC]

204103 reported adverse events

Drugs of this class: NATALIZUMAB VEDOLIZUMAB

These side effects are most commonly reported by patients taking drugs of the Integrin Receptor Antagonist [EPC] class:

# Side effect Count
0 FATIGUE 20509
1 MULTIPLE SCLEROSIS RELAPSE 15247
2 HEADACHE 10830
3 DRUG INEFFECTIVE 10129
4 OFF LABEL USE 10123
5 GAIT DISTURBANCE 9234
6 MULTIPLE SCLEROSIS 8521
7 ASTHENIA 8368
8 FALL 8075
9 MALAISE 8044
See all common reactions for Integrin Receptor Antagonist [EPC]

Drugs of the Integrin Receptor Antagonist [EPC] class are most commonly taken among patients reporting these side effects:

# Side effect Count Frequency
0 THERAPEUTIC REACTION TIME DECREASED 1101 0.8872
1 DRUG DELIVERY DEVICE IMPLANTATION 121 0.5500
2 INFUSION SITE HAEMATOMA 141 0.4578
3 LOSS OF THERAPEUTIC RESPONSE 250 0.4554
4 JC VIRUS TEST POSITIVE 382 0.4515
5 POOR VENOUS ACCESS 2387 0.3996
6 NEUTRALISING ANTIBODIES POSITIVE 113 0.3767
7 AGRAPHIA 185 0.3537
8 GENERAL SYMPTOM 2193 0.3513
9 OPPORTUNISTIC INFECTION 461 0.3158
See all enriched reactions for Integrin Receptor Antagonist [EPC]